Merrimack Pharmaceuticals, Inc.

Ipsen Biopharm Limited

Ispen Biopharm Ltd.

Jonathan Basil Fitzgerald

Victor Mandla Moyo

Eliel Bayever

Clet Niyikiza

Navreet Dhindsa

Peter Laivins

Jaeyeon Kim

Alexey Alexandrovich Lugovskoy

Sharlene Adams

Neeraj Kohli

Lihui Xu

Bryan Johnson

Jason Baum

Sarah F Blanchette

Daryl C Drummond

Helen Lee

Ashish Kalra

Ulrik Bjerl Nielsen

Birgit Schoeberl

Matthew D Onsum

Brian Harms

Bart S Hendriks

William Kubasek

Daniel F Gaddy

Bambang Adiwijaya

Bin Zhang

Stephan Braun

Shannon Leonard

Francis David Gibbons

Victor Moyo

Matthew David Onsum

Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

Methods for treating pancreatic cancer using combination therapies

Combination therapies for treating cancer comprising administration of a topoisomerase-1 inhibitor and a PARP inhibitor are provided. The topoisomerase-1 inhibitor can be delivered as a liposomal formulation that provides for prolonged accumulation of the topoisomerase-1 inhibitor within a tumor relative to outside of the tumor. Therapeutic benefit can thereby be obtained by delaying the administration of the PARP inhibitor after each administration of a liposomal irinotecan formulation until the accumulation of the topoisomerase inhibitor in the tumor is sufficiently greater than outside the tumor to result in increased efficacy of the PARP inhibitor and topoisomerase inhibitor within the tumor, while reducing the peripheral toxicity of the combination therapy. The therapies disclosed herein are useful in the treatment of human cancers with solid tumors, including cervical cancer.

Combination therapy for cancer treatment

Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.

Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin

Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.

Nanoliposomal irinotecan for use in treating small cell lung cancer

Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of gastric cancer, including treatment of patients diagnosed with previously untreated gastric cancer. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.

Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)

Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan

Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.

Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies

Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodies

Growing community of inventors

Arlington, MA, United States of America

Jonathan Basil Fitzgerald